<DOC>
	<DOCNO>NCT01611025</DOCNO>
	<brief_summary>This retrospective , multicentre , observational study ass trend antibiotic utilization hospital ecology respect susceptibility pattern select bacterial isolates utilized antibiotic .</brief_summary>
	<brief_title>Hospital Microbial Ecology Follow Introduction Ertapenem Other Newly Introduced Antibiotic Over Time</brief_title>
	<detailed_description>This retrospective , multicentre , observational study ass trend antibiotic utilization hospital ecology respect susceptibility pattern select bacterial isolates utilized antibiotic . There two set data collect : Hospital acquire infection ( first pathogen culture episode ) All infection ( whole hospital susceptibility data ) Primary Objectives : 1 . To study impact introduction ertapenem susceptibility pattern various pathogen imipenem/meropenem . 2 . To study impact introduction ertapenem susceptibility Gram negative bacillus antimicrobial agent commonly use participate study site . 3 . To explore trend antimicrobial utilization introduction new antimicrobial agent hospital formulary index period . Secondary Objectives : 1 . To study trend antimicrobial susceptibility ESBL-producing Enterobacteriaceae index period 2 . To study impact introduction newly introduce antibiotic ( e.g. , tigecycline ) susceptibility pattern various pathogen carbapenems 3 . To study prevalence trend Pan drug resistant Acinetobacter baumannii Pseudomonas aeruginosa resistant index period Exploratory objective : 1 ) To explore resistant rate ESBL-producing Enterobacteriaceae , Pan drug resistant Acinetobacter baumannii Pseudomonas aeruginosa different hospital adjust DDD . Hypotheses : 1 . There increase utilization rate antibiotic , specifically carbapenem drug ( imipenem , meropenem ) index period ( 2-3 year 2-3 year introduction ertapenem ) . 2 . The introduction ertapenem institution formulary negatively impact susceptibility select bacterial isolates carbapenem antibiotic .</detailed_description>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>susceptibility Pseudomonas aeruginosa susceptibility Escherichia coli ( ESBL NonESBL produce strain ) susceptibility Klebsiella pneumoniae ( ESBL NonESBL produce strain ) susceptibility Enterobacter cloaca susceptibility Enterobacter aerogenes susceptibility Acinetobacter baumannii antibiotic utilization data carbapenems : Ertapenem , Meropenem , Imipenem antibiotic utilization data Penicillins : Piperacillin/Tazobactam antibiotic utilization data cephalosporin : Ceftriaxone , Cefotaxime , Flomoxef , Cefoperazone , Ceftazidime , cefepime , Cefpirome antibiotic utilization data Aztreonam , antibiotic utilization data fluoroquinolones : Ciprofloxacin , Levofloxacin antibiotic utilization data aminomethylcyclines : Tigecycline</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>